Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson (NYSE: JNJ) announced an expansion of its partnership with the Biomedical Advanced Research and Development Authority (BARDA) to further develop its investigational COVID-19 vaccine. Janssen will invest approximately $604 million, while BARDA will contribute $454 million, supporting the Phase 3 ENSEMBLE trial with up to 60,000 volunteers. This collaboration emphasizes the importance of public-private partnerships in addressing the COVID-19 pandemic. J&J reaffirms its commitment to ethical vaccine development and adherence to scientific standards.
Johnson & Johnson will host a virtual Medical Devices Update on November 19, 2020, at 10 a.m. ET, showcasing innovations in digital surgery. The session will feature leadership insights, including those from Ashley McEvoy, and will cover the company's strategic positioning and advancements in Orthopaedics, Surgery, Interventional Solutions, and Vision franchises. Attendees can view franchise exhibits starting November 18, 2020, at 4:30 p.m. ET. Registration is available online, and a replay will be accessible post-event on the Investor Relations section of the JNJ website.
Johnson & Johnson (NYSE: JNJ) announced a cash dividend of $1.01 per share for the fourth quarter of 2020. This dividend will be paid on December 8, 2020 to shareholders recorded by the close of business on November 24, 2020. The ex-dividend date is set for November 23, 2020. This announcement reflects the company's commitment to returning value to its shareholders amidst its ongoing operations in the health care sector.
Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 results showing solid performance with reported sales of $21,082 million, a 1.7% increase from 2019. Net earnings surged 102.7% to $3,554 million, with diluted EPS at $1.33, reflecting a 101.5% growth. The Pharmaceutical segment grew 5.0%, leading overall growth, while Medical Devices faced a 3.6% decline impacted by COVID-19. New regulatory approvals and ongoing vaccine development were highlighted, showcasing the company's commitment to innovation.
Johnson & Johnson (NYSE: JNJ) announced an agreement with the European Commission to supply 200 million doses of its COVID-19 vaccine candidate to EU Member States, with the option for an additional 200 million doses. This follows ongoing discussions with stakeholders to improve global access to the vaccine. Johnson & Johnson plans to allocate 500 million doses for lower-income countries, starting mid-next year upon regulatory approval. The vaccine leverages AdVac technology, previously used in other vaccine candidates. The Phase 3 clinical trial is underway, evaluating a single-dose regimen.
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Momenta Pharmaceuticals for approximately $6.5 billion in cash. The tender offer for Momenta's shares was for $52.50 per share, with about 79.4% of shares tendered. The acquisition, effective October 1, 2020, allows Momenta to operate as a wholly-owned subsidiary, focusing on therapies for rare diseases and autoimmune disorders. The merger is anticipated to enhance patient care and facilitate multiple product launches in areas of significant unmet need.
Johnson & Johnson announced the initiation of its Phase 3 trial (ENSEMBLE) for the COVID-19 vaccine candidate, JNJ-78436735, after positive interim results from earlier studies. This pivotal trial aims to enroll 60,000 volunteers across multiple countries to assess the vaccine's safety and efficacy. The company plans to produce one billion doses annually, aiming for emergency use authorization in early 2021. The trial emphasizes diversity, including significant representation of vulnerable populations, and reflects J&J's commitment to transparency and collaboration with health authorities.
Johnson & Johnson (NYSE:JNJ) has announced its acquisition of Momenta Pharmaceuticals for approximately $6.5 billion in cash. This strategic move aims to enhance Janssen's position in treating immune-mediated diseases, particularly through the lead asset nipocalimab, an anti-FcRn antibody. The acquisition is expected to provide global rights to nipocalimab, which could expand treatment options for autoantibody-driven diseases affecting 195 million individuals globally. The transaction is projected to close in the second half of 2020 and is anticipated to be modestly dilutive to JNJ's earnings in 2021.
Johnson & Johnson announced an agreement with the U.S. government to manufacture and deliver 100 million doses of its COVID-19 vaccine candidate, Ad26.COV2.S, pending FDA approval. The U.S. government, through BARDA, is committing over $1 billion for this initiative. Additionally, there is an option for the purchase of 200 million more doses. A Phase 1/2a clinical trial is currently underway in the U.S. and Belgium. The company aims to supply over 1 billion doses globally by 2021, following regulatory approval.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
